IBD (inflammatory bowel syndrome) can drastically disrupt a person’s life. With symptoms ranging from severe abdominal pain, diarrhea, and fatigue, to drastic weight loss, IBD patients often find themselves challenged to work, go to school, or participate in any social activities. What’s more, they are at an increased risk of complications, such as bowel obstructions, malnutrition, and colorectal cancer.
Healthcare accessibility is one of the pressing issues that IBD patients face regularly. For one, IBD requires specialized care from gastroenterologists and medical facilities equipped to diagnose and manage these conditions. However, many regions lack sufficient specialized care, forcing patients to travel long distances, often at great expense, to receive treatment. What’s more, IBD medications can be expensive and are not always covered by insurance. This leaves many patients with limited treatment options or forces them to make difficult choices between their health and financial stability.
Fighting the Steep Rise of IBD Cases
Over the last several years, the global cases of IBD see an unprecedented rise. According to research by GlobalData, Crohn’s disease cases are expected to be notably prominent within the eight countries – United States, France, Germany, Italy, Spain, the United Kingdom, Japan, and Canada – highlighting the growing importance of global access to IBD treatment.
Paving the way is Evinature, a startup that leads cutting-edge research in integrative therapies for IBD. The company sources, develops, and distributes clinically-proven nutraceuticals, providing patients around the world with access to accurate diagnosis and treatment through their proprietary online platform.
Just recently, Evinature partnered with Adacyte Therapeutics, a multinational company that promotes innovative therapies and solutions for complex diseases. Starting in October, Adacyte will have exclusive sales and distribution rights of Evinature’s CurQD – a curcumin-QingDai combination for the treatment of moderate to severe ulcerative colitis, a form of IBD. Distribution will start in Spain, with plans on expanding to Portugal shortly after. This partnership will enable IBD patients in Spain and Portugal to go directly to their physicians for a prescription or access their own digital pathway where they can complete an online assessment, order online, and return for follow-ups.
Evinature CEO and Co-Founder Apan Amos Damri shares that Adacyte Therapeutics stood out due to the company’s lengthy experience with IBD patients, GI physicians, and the Spanish medical system: “After visiting them in Barcelona and becoming acquainted with their staff and management, we realized this connection could greatly benefit IBD patients in Spain and Portugal, making it easier and more convenient for them to access CurQD and undergo treatment with the close collaboration of their physicians.”
“We at Adacyte are very pleased with this new partnership and very excited to commercialize CurQD in Spain,” says Christian Izcara, Managing Director at Adacyte. “The essence of both, Evinature and Adacyte, is their commitment to address medical needs that cannot be met by pharmaceutical treatment alone. This collaboration demonstrates Adacyte´s strategy of leveraging our expertise in IBD to continue providing innovative and distinctive solutions. We believe even more strongly that Evinature´s unique compound, CurQD, can become a fundamental treatment option for patients and physicians struggling to control IBD.”
Apan further explains that collaborating closely with healthcare professionals and medical facilities is a pivotal factor in determining the overall well-being and outcomes of patients. This synergy between patients and their medical teams plays an integral role in navigating the complex landscape of healthcare. “We see in the U.S. medical system a greater adherence to our treatment than other treatments,” Apan says. “We believe this is because the physicians we work with are not only aware of the entire underlying situation but also have a direct source of information when it comes to our nutraceuticals, protocols, and research. Working with more doctors is our greatest opportunity to improve patient adherence and outcomes.”
What’s Next for Evinature?
Next month, Apan, Nir Salomon, and Shomron Ben-Horin, M.D. will be joining a symposium in Madrid, where they’ll introduce the products, protocols, and research to leading IBD doctors.
“We’ve already started training medical representatives, who are eager to provide these treatments to their patients,” Apan concludes. “We’ve also received offers from Greece, Turkey, and other European countries. Once we’ve completed a successful launch in Spain, we’re excited to expand further across the globe.”
